Emerging therapies for Clostridium difficile infections

Abstract

Introduction: Clostridium difficile infection (CDI) is the leading identifiable gastrointestinal disease in healthcare institutions, but the response rates to the two standard therapies for CDI are declining and so innovative therapies are being developed for CDI. The purpose of this paper is to review the data on the efficacy and safety of emerging therapies for CDI and assess their potential for effectiveness based on the clinical phase of development and marketing challenges.

Areas covered: Emerging therapies for CDI are reviewed including new antibiotics, peptides, immune regulators, probiotics and toxin binders. PubMed, Medline and Google Scholar and online clinical trial registers are searched from 1976 to 2010 for articles unrestricted by language. Secondary searches by author, manufacturing companies and FDA websites are also performed.

Expert opinion: Of the emerging therapies for CDI, several may ultimately reduce the incidence of CDI and the economic burden of this disease on the healthcare system. Several emerging treatments (fidaxomicin, rifaximin and mAbs) show the most promise, although only one is currently being actively developed. Use of other clostridial strains, probiotic strains and immune enhancers have great potential as therapies, but require further development.

Keywords::

• antibiotics
• Clostridium difficile
• diarrhea
• epidemiology
• gastrointestinal
• immune globulin therapies
• nosocomial
• outbreaks
• probiotics
• therapies

Acknowledgements

The views expressed in this article are those of the author and do not represent the views of the Department of Veterans Affairs.

Notes